Depsides isolated from the Sri Lankan lichen Parmotrema sp. exhibit selective Plk1 inhibitory activity

Pharmaceutical Biology

Volumn 49, Issue 3, 2011, Pages 296-301

  Williams, David E ^a   Loganzo, Frank ^b   Whitney, Lauren ^b   Togias, Jenny ^b   Harrison, Richard ^b   Singh, Maya P ^b   McDonald, Leonard A ^b   Kathirgamanathar, Selvaluxmy ^c   Karunaratne, Veranja ^c   Andersen, Raymond J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b PFIZER INC   (United States)

^c UNIVERSITY OF PERADENIYA   (Sri Lanka)

Author keywords

differential activity; Mitotic kinases; purified recombinant Plk1 kinase

Indexed keywords

ADENOSINE TRIPHOSPHATE; BETA ALECTOTRONIC ACID; BETA COLLATALIC ACID; DEPSIDE; PARMOTREMA EXTRACT; PLANT EXTRACT; POLO LIKE KINASE 1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ISOLATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME BINDING; ENZYME INHIBITION; IC 50; LICHENS; NONHUMAN; PARMOTREMA; SRI LANKA;

AMINO ACID SEQUENCE; ASCOMYCOTA; CELL CYCLE PROTEINS; DEPSIDES; HUMANS; LICHENS; MOLECULAR SEQUENCE DATA; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SRI LANKA;

PARMELIACEAE; PARMOTREMA;

EID: 79951729240     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2010.517540     Document Type: Article

References (20)

1. Barr FA, Silljé HH, Nigg EA. (2004). Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5:429-440. (Pubitemid 38745493)
2. Blagden S, de Bono J. (2005). Drugging cell cycle kinases in cancer therapy. Curr Drug Targets 6:325-335. (Pubitemid 40667798)
3. Gray PJ Jr, Bearss DJ, Han H, Nagle R, Tsao MS, Dean N, Von Hoff DD. (2004). Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 3: 641-646. (Pubitemid 39193743)
4. Jayaprakasha GK, Rao LJ. (2000). Phenolic constituents from the lichen Parmotrema stuppeum (Nyl.) Hale and their antioxidant activity. Z Naturforsch, C, J Biosci 55:1018-1022. (Pubitemid 32111241)
5. Jiang N, Wang X, Yang Y, Dai W. (2006). Advances in mitotic inhibitors for cancer treatment. Mini Rev Med Chem 6:885-895. (Pubitemid 44194376)
6. Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C, Strebhardt K. (1999). Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 59:2794-2797. (Pubitemid 29283110)
7. Krivoshchekova OE, Mishchenko NP, Stepanenko LS, Maksimov OB. (1983). Aromatic metabolites of Parmeliaceae lichens. I. Depsidones. Khimiya Prirodnykh Soedinenii 1:13-19.
8. Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, Noro N, Furuta M, Emmitte KA, Gilmer TM, Mook RA Jr, Cheung M. (2007). In vitro biological activity of a novel smallmolecule inhibitor of polo-like kinase 1. Mol Cancer Ther 6: 450-459. (Pubitemid 46332447)
9. Liu X, Erikson RL. (2003). Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 100:5789-5794. (Pubitemid 36576886)
10. Liu Y, Jiang N, Wu J, Dai W, Rosenblum JS. (2007). Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects. J Biol Chem 282:2505-2511. (Pubitemid 47076790)
11. McInnes C, Mazumdar A, Mezna M, Meades C, Midgley C, Scaerou F, Carpenter L, Mackenzie M, Taylor P, Walkinshaw M, Fischer PM, Glover D. (2006). Inhibitors of polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol 2:608-617. (Pubitemid 44610345)
12. Mito K, Kashima K, Kikuchi H, Daa T, Nakayama I, Yokoyama S. (2005). Expression of polo-like kinase (PLK1) in non-Hodgkin s lymphomas. Leuk Lymphoma 46:225-231. (Pubitemid 40185952)
13. Rangaswami S, Rao SV. (1955). Chemical components of Parmelia species of India. Indian J Pharm 7:50-53.
14. Smith MR, Wilson ML, Hamanaka R, Chase D, Kung H, Longo DL, Ferris DK. (1997). Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun 234:397-405. (Pubitemid 27243915)
15. Spänkuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K. (2004). Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 96:862-872. (Pubitemid 38807607)
16. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Rettig WJ. (2007). BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17:316-322. (Pubitemid 46241881)
17. Strebhardt K, Ullrich A. (2006). Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6:321-330.
18. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y, Saji S. (2003). Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 94:148-152. (Pubitemid 36575873)
19. Takai N, Miyazaki T, Fujisawa K, Nasu K, Hamanaka R, Miyakawa I. (2001). Expression of polo-like kinase in ovarian cancer is associated with histological grade and clinical stage. Cancer Lett 164:41-49. (Pubitemid 32144988)
20. Weichert W, Schmidt M, Gekeler V, Denkert C, Stephan C, Jung K, Loening S, Dietel M, Kristiansen G. (2004). Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 60:240-245. (Pubitemid 38971835)